Quarterly results: Avecho; Melodiol; Bioxyne/BLS; Emyria; Ecofibre; Zelira; Elixinol; AusCann; Botanix by Steve Jones and Martin Lane January 31, 2024July 11, 2024 Avecho Biotechnology will begin its low-dose CBD phase III clinical trial in the next two months […]
Administrator ponders offers for Bod assets ahead of report to creditors by Steve Jones January 30, 2024July 16, 2024
‘We have to do something, we can’t just sit on our hands’ by Steve Jones January 30, 2024July 16, 2024
Coming up trumps: how Australian patients are reaping the rewards of a $50 bet by Steve Jones January 24, 2024July 16, 2024
Hunt for Medlab buyer drew ‘bottom feeders’, says MD as plan unfolds to deliver shareholder return by Steve Jones January 17, 2024July 11, 2024
SAS-B deep dive: more women turn to flower and anxiety on the rise as cannabis sands continue to shift by Steve Jones January 17, 2024July 11, 2024
ODC spells out cannabis vape import reforms and flags further TGO 93 review by Steve Jones January 17, 2024July 11, 2024
Leading prescriber leaves corporate world behind to plough furrow as ‘entirely independent clinician’ by Steve Jones January 16, 2024July 11, 2024
Looking to expand overseas? Here’s what you need to know by Michael Sassano January 10, 2024July 11, 2024
